Back to Search
Start Over
Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
- Source :
- Современная онкология, Vol 23, Iss 2, Pp 287-291 (2021)
- Publication Year :
- 2021
- Publisher :
- IP Habib O.N., 2021.
-
Abstract
- Extensive-stage small cell lung cancer (ES-SCLC) is characterized by an aggressive course, a high recurrence rate and fast progression. For a long time, the survival prognosis for the most patients suffering from this disease remained unfavorable. The situation changed with the appearance of chemoimmunotherapy in clinical practice. Chemotherapy based on durvalumab in comparison with the standard chemotherapy demonstrated the statistically and clinically significant increase in median overall survival in patients with previously untreated ES-SCLC in the CASPIAN international trial. This article deals with the case of the application of standard chemotherapy in combination with durvalumab as a first-line ES-SCLC therapy. The patient started receiving durvalumab therapy in June 2017 as a part of the CASPIAN international trial. In March 2021 the duration of therapy was 45 months, the patient had a complete regression of the disease.
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Durvalumab
business.industry
durvalumab
medicine.medical_treatment
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immunotherapy
Disease
extensive-stage small cell lung cancer
immune checkpoint inhibitors
anti-pd-l1-antibody
Chemoimmunotherapy
Survival prognosis
Internal medicine
chemoimmunotherapy
medicine
In patient
business
Extensive-stage small cell lung cancer
RC254-282
Subjects
Details
- Language :
- Russian
- ISSN :
- 18151442 and 18151434
- Volume :
- 23
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Современная онкология
- Accession number :
- edsair.doi.dedup.....a17e51facdd2c45ab91b765434aad8ea